Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression

This study demonstrates that combining pharmacologic inhibition of fatty acid synthase (FASN) with dietary polyunsaturated fatty acid (PUFA) supplementation suppresses prostate cancer progression by inducing lethal oxidative stress through increased lipid peroxidation and mitochondrial dysfunction.

The Gist

The Big Picture: Starving the Cancer's Kitchen

Imagine a prostate cancer cell as a greedy chef running a restaurant. To keep the restaurant open (growing and spreading), this chef needs a massive amount of ingredients, specifically fats.

Normally, this chef has a super-efficient in-house factory (an enzyme called FASN) that takes basic raw materials and instantly manufactures the specific fats the cancer needs to build its walls and power its engines. This factory is so good that the cancer doesn't really need to buy much from the outside; it makes almost everything it needs itself.

The researchers asked a clever question: What happens if we shut down the in-house factory and force the chef to rely entirely on the grocery store for ingredients?

The Experiment: The "Bad" Grocery Delivery

The scientists tried two things:

1. Shut down the factory: They used drugs to stop the cancer cell from making its own fats (inhibiting FASN).
2. Change the grocery delivery: Instead of sending the chef "safe" fats (like saturated fats found in butter or meat), they flooded the system with Polyunsaturated Fatty Acids (PUFAs). Think of PUFAs as "unstable, volatile ingredients" (like highly flammable oil) that the cancer cell usually avoids making itself but can grab if it has to.

What Happened? The "House of Cards" Collapses

When the cancer cell's factory was shut down, it was forced to grab these unstable PUFAs from the "grocery store" (the diet or the blood) to build its cell walls. This created a disaster inside the cell:

1. The Walls Became Brittle: Imagine building a house out of glass instead of brick. The cell membrane became full of these unstable PUFAs.
2. The "Fire" Started: Because these PUFAs are chemically unstable, they react easily with oxygen. This caused a massive oxidative stress event—essentially, the cell started rusting and burning from the inside out.
3. The Engine Overheated: The cell's power plants (mitochondria) got confused. They tried to work harder to fix the damage but ended up overheating (hyperpolarization) and producing toxic waste (Reactive Oxygen Species).
4. The Result: The cell couldn't handle the internal fire and the structural weakness. It essentially self-destructed.

The "Rescue" Attempt (And Why It Failed)

The researchers also tested if they could "save" the cancer cell by giving it back the "safe" fats (saturated fats) it usually makes.

• Result: When they gave the cell safe fats, the cell stopped dying. This proved that the cancer was dying specifically because it was forced to use the "unstable" fats.

The Mouse Study: Diet Matters More Than You Think

The team then moved to mice that naturally develop prostate cancer. They put the mice on two different diets:

• Diet A (The "Bad" Diet): High in saturated fats (like a standard Western diet).
• Diet B (The "Good" Diet): High in PUFAs (like Omega-3s found in fish).

The Surprising Finding:

• Mice on the PUFA-rich diet developed much less aggressive cancer, even without any drugs. The "unstable" ingredients in their food made the cancer cells weak and prone to self-destruction.
• Mice on the Saturated fat diet kept growing cancer, even when given the drug to shut down the factory. The cancer just used the abundant "safe" fats from the diet to keep building its walls.

The Takeaway: A New Strategy for Treatment

This paper suggests a powerful new way to fight prostate cancer: Don't just attack the cancer; change its diet.

• The Strategy: Use drugs to stop the cancer from making its own fats, and simultaneously feed the patient a diet rich in Omega-3s (PUFAs).
• The Analogy: It's like locking the doors to the cancer's kitchen (the drug) and then throwing a bucket of gasoline (the PUFAs) into the room. The cancer tries to use the gasoline to build its house, but the house immediately catches fire and burns down.

In short: By forcing cancer cells to rely on unstable fats they can't make themselves, we can make them explode from the inside, while healthy cells (which are better at managing these fats) remain safe. This opens the door for combining specific drugs with specific diets to treat prostate cancer more effectively.

Technical Summary

1. Problem Statement

Prostate cancer (PCa) cells exhibit a metabolic reprogramming characterized by a heavy dependence on de novo lipogenesis (DNL), driven by the overexpression of Fatty Acid Synthase (FASN). FASN produces saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs), which are essential for membrane biosynthesis, energy metabolism, and androgen receptor (AR) signaling. While pharmacological inhibition of FASN has shown promise, tumors often develop resistance or rely on compensatory mechanisms. The authors hypothesized that blocking endogenous SFA/MUFA synthesis while simultaneously enriching the tumor microenvironment with exogenous polyunsaturated fatty acids (PUFAs) could create a lethal metabolic vulnerability. Specifically, they investigated whether forcing cancer cells to incorporate oxidation-prone PUFAs into their membranes (due to a lack of stable SFAs) would induce lethal oxidative stress and ferroptosis.

2. Methodology

The study employed a multi-modal approach combining in vitro cell biology, 3D organoid models, and in vivo genetically engineered mouse models (GEMM).

• Cell Models: Hormone-sensitive (LNCaP) and castration-resistant (22Rv1, C4-2) human prostate cancer cell lines.
• Organoid Models: Human (MSK-PCa3) and murine (Hi-Myc) prostate cancer organoids.
• Pharmacological Interventions:
  • FASN Inhibitors (FASNi): IPI-9119 (inhibits $\beta$-ketoacyl reductase domain) and TVB-2640/TVB-3664 (inhibit thioesterase domain).
  • PUFA Supplementation: Docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), and Docosapentaenoic acid (DPA).
  • Rescue Agents: Ferrostatin-1 (Fer-1) to inhibit lipid peroxidation.
• In Vivo Model: Hi-Myc mice (overexpressing c-MYC in prostatic epithelium) were randomized to two isocaloric diets:
  • HSD: High Saturated/MUFA diet.
  • HPD: High PUFA diet.
  • Mice were treated with TVB-3664 (oral gavage) or vehicle.
• Analytical Techniques:
  • Metabolism: Seahorse XF analysis (OCR/ECAR) for mitochondrial respiration and glycolysis.
  • Lipidomics: LC-ESI/MS/MS to profile phospholipids, neutral lipids, and fatty acid composition in cells, serum, and tissue.
  • Oxidative Stress: Measurement of ROS (MitoSOX), mitochondrial membrane potential (JC-1), lipid peroxidation (BODIPY C11), and protein carbonylation.
  • Histopathology: H&E staining and AI-assisted quantification of tumor burden (PIN vs. invasive carcinoma).

3. Key Contributions

• Mechanistic Insight: The study elucidates that FASN inhibition does not merely starve cells of lipids but actively remodels membrane composition, forcing the incorporation of exogenous PUFAs. This creates a "lipid peroxidation trap."
• Synergistic Strategy: It demonstrates that combining FASN inhibition with dietary or exogenous PUFA supplementation is significantly more effective than either treatment alone.
• Diet-Drug Interaction: It establishes that dietary lipid composition is a critical determinant of therapeutic efficacy, capable of modulating the response to metabolic inhibitors in vivo.
• Biomarker Identification: Identifies tripalmitin (TG 16:0/16:0/16:0) depletion as a pharmacodynamic biomarker for DNL suppression and effective dietary intervention.

4. Key Results

A. Metabolic and Bioenergetic Effects

• Mitochondrial Stress: FASN inhibition impaired ATP-linked respiration and basal mitochondrial respiration in both hormone-sensitive and castration-resistant cells. Unlike some metabolic inhibitors, it did not trigger a compensatory glycolytic shift (ECAR remained stable), indicating a collapse in oxidative metabolism.
• Membrane Remodeling: FASN inhibition depleted SFAs/MUFAs, leading to a compensatory uptake of exogenous PUFAs. This resulted in:
  • Increased abundance of PUFA-containing phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
  • Altered ether-lipid ratios (increased PC-P/PE-P ratio), inducing membrane rigidity and ER stress (upregulation of BiP).
  • Upregulation of ACSL4 (promoting PUFA esterification) and downregulation of GPX4 (reducing antioxidant capacity), priming cells for ferroptosis.

B. Oxidative Damage and Cell Death

• Synergy: The combination of FASNi + DHA (or EPA/DPA) caused a synergistic increase in:
  • Intracellular superoxide and mitochondrial hyperpolarization.
  • Lipid peroxidation and protein carbonylation.
  • Cell death in 2D cultures and 3D organoids.
• Mechanism Validation: The cell death was partially rescued by Ferrostatin-1, confirming that lipid peroxidation is a primary driver. However, the involvement of ER stress and apoptosis markers suggests a multi-pathway cell death mechanism.
• Preference: When both palmitate (SFA) and DHA (PUFA) were available, FASN-inhibited cells preferentially incorporated palmitate, suggesting the toxicity is specific to the forced incorporation of PUFAs when SFAs are scarce.

C. In Vivo Efficacy (Hi-Myc Mice)

• Dietary Impact: Mice fed the High PUFA Diet (HPD) showed a significant reduction in the progression to invasive adenocarcinoma compared to the High Saturated Diet (HSD) (21.4% vs. 60% incidence).
• Drug-Diet Interaction:
  • In the HSD background, FASN inhibition alone did not significantly reduce invasive carcinoma, likely because dietary SFAs compensated for the blocked DNL.
  • In the HPD background, the diet itself was highly protective. The combination of HPD + FASNi did not show a statistically additive benefit over HPD alone in this specific model, suggesting the dietary intervention was the dominant factor in preventing invasion.
• Lipidomic Convergence: Both HPD and FASNi led to the depletion of tripalmitin and PUFA-enriched phospholipids in serum and tissue, confirming that the diet successfully altered the systemic and tumoral lipidome to mimic the metabolic state induced by the drug.

5. Significance and Clinical Implications

• Therapeutic Window: The study defines a "metabolic window" where prostate tumors are vulnerable to oxidative stress when deprived of endogenous SFAs and forced to rely on oxidizable PUFAs.
• Nutritional Oncology: It provides strong preclinical evidence that dietary lipid composition is not a passive background factor but an active therapeutic variable. A PUFA-enriched diet may potentiate FASN-targeted therapies (e.g., TVB-2640) or serve as a standalone strategy to delay progression.
• Clinical Translation:
  • Supports ongoing clinical trials combining FASN inhibitors with AR-targeted therapies.
  • Suggests that patient stratification based on lipidomic profiles (e.g., DNL reliance) could optimize treatment.
  • Proposes tripalmitin levels as a biomarker to monitor drug efficacy and dietary compliance.
• Future Directions: The authors note the need to investigate tumor heterogeneity (e.g., neuroendocrine PCa) and the specific determinants that bias cell death toward ferroptosis versus apoptosis to refine combination strategies.

In conclusion, this paper demonstrates that suppressing the synthesis of stable lipids while flooding the system with unstable, oxidation-prone lipids creates a lethal metabolic crisis in prostate cancer, offering a novel dual-pronged strategy involving pharmacology and nutrition.